James Maitland brings a unique perspective to the intersection of medical technology and market dynamics. Having witnessed how advanced robotics and IoT can streamline care, he also understands the fragile balance of hospital competition and the heavy toll that administrative shifts take on patient outcomes. This conversation delves into the controversial Certificate of Public Advantage (COPA) in Tennessee, examining the risks of allowing state-sanctioned monopolies like Ballad Health to operate without oversight. We explore the consequences of escalating healthcare costs, the reality of emergency room inefficiencies, and the regulatory vacuum created when state supervision ends before a competitive market can take its place.
When a state oversight agreement for a hospital monopoly expires before new competitors enter the market, what specific risks arise regarding patient costs? How should regulators balance the desire for market-driven competition against the immediate need for price and quality protections?
The primary risk is that a hospital system gains the ability to exercise substantial market power without any check from either the state or a competitor. We have seen this play out in other markets, such as with Mission Health in North Carolina, where commercial inpatient prices surged by 25% while a COPA was in place and then jumped at least another 38% once it was repealed. This creates a terrifying scenario for patients who find themselves trapped in a geographic region where a single entity controls their health with no accountability. Regulators must realize that the “worst possible outcome” occurs when a hospital evades antitrust scrutiny at the beginning through a state agreement and then evades state oversight at the end by letting that agreement expire. To find a balance, specific economic protections—such as hard caps on price increases—must remain in force until a competing acute care hospital is actually open and operational, rather than just planned.
Emergency room wait times can sometimes triple following a major hospital merger, even under state supervision. What operational steps can management take to reverse these trends, and what performance indicators should be prioritized to ensure that patient access doesn’t continue to erode during a transition in oversight?
To reverse the trend where emergency room wait times have tripled, as we saw following the 2018 merger that created Ballad Health, management must move away from a model that prioritizes consolidation over clinical throughput. They need to invest heavily in front-end triage and perhaps integrate IoT solutions that track patient flow in real-time to identify bottlenecks before they become dangerous. The state’s monitoring officials have noted that grading systems often allow these monopolies to continue operating even when they repeatedly fail to meet basic quality-of-care standards. Therefore, we should prioritize indicators like “time-to-physician” and “patient-to-staff ratios” as non-negotiable metrics that carry heavy financial penalties if ignored. Without these strict operational guardrails, the convenience of the monopoly will always overshadow the urgent, sensory reality of a patient waiting hours in a cold, crowded hallway for life-saving attention.
If a healthcare system avoids federal antitrust scrutiny through a state-sanctioned merger but then sees that state supervision end, what prevents it from exercising unchecked market power? What specific legal or economic mechanisms should be established to protect rural patients during this regulatory vacuum?
In a regulatory vacuum, the only remaining line of defense is the State Attorney General, who theoretically acts independently to enforce state and federal antitrust laws. However, as the FTC points out, subsequent legal actions are often unable to undo the fundamental harm of an anticompetitive merger once the original systems have been fully integrated. To protect rural patients who have no other options, states should implement “tail-end” restrictions that extend oversight of care quality and service availability long after the primary COPA expires. For example, Tennessee is looking at keeping price restrictions in place until 2033, which provides a decade-long cushion against sudden spikes. We must also ensure that population health initiatives are legally mandated as a condition of the merger’s existence, ensuring that the system cannot simply prune away less profitable rural clinics to boost their bottom line.
Many believe removing Certificate of Need requirements will spark competition, yet a multi-year gap between ending oversight and allowing new facilities can be problematic. How should a state synchronize these policy changes to ensure a seamless transition?
Synchronization is everything because a gap in timing creates a window for a monopolist to engage in unchecked anticompetitive behavior. If a state repeals a COPA in 2028 but doesn’t remove Certificate of Need (CON) restrictions for new acute-care hospitals until 2030, you are essentially handing the incumbent a two-year “free pass” to hike prices and lower standards before any rival can even break ground. The timeline for building a new, functional hospital facility is significant, often requiring years of planning, permitting, and construction. To make the impact on pricing realistic, the CON requirements should be axed immediately or even before the COPA expires to give competitors a head start. Only by streamlining the entry of new providers can we hope to restore the competition that was lost during the initial formation of the monopoly.
Dramatic price increases have been observed in certain markets once state-monitored hospital agreements are repealed. In such scenarios, how can local governments and employers maintain healthcare affordability for their communities?
When the regulatory safety net is pulled away, local governments and large employers often find themselves at the mercy of a single provider’s demands. These stakeholders must leverage their collective bargaining power to demand transparency and multi-year rate stability agreements that mirror the old COPA protections. The long-term consequences for population health are dire; if affordability vanishes, patients skip preventative screenings or ignore chronic conditions, which eventually leads to a more expensive and less healthy community. We’ve seen that once these hospital systems are free from state supervision of care quality, the focus shifts from community well-being to maximizing the revenue generated by their monopolistic footprint. Local leaders must remain vigilant and use every legislative tool available to ensure that “market power” does not become synonymous with “community exploitation.”
What is your forecast for the future of hospital monopolies and state-led oversight agreements?
I believe we are entering an era of deep skepticism regarding the efficacy of COPAs, as the federal government continues its long campaign against these mechanisms across multiple administrations. While sixteen states currently use COPA laws to try and save struggling rural hospitals from closure, the data increasingly shows that the trade-off—higher costs and lower quality—is a heavy burden for the public to bear. In the coming decade, I expect to see a shift toward more aggressive federal intervention to prevent these mergers from happening in the first place, rather than trying to manage them through “state-sanctioned” oversight. Ultimately, we will likely see a move toward more transparent, competitive models where technology and new facility entries are prioritized over the preservation of monolithic, legacy systems. The “Tennessee experiment” with Ballad Health will serve as a cautionary tale for other legislatures considering whether a monopoly can ever truly be managed in the public’s best interest.
